SNDX — Syndax Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $1.22bn
- $1.25bn
- $172.35m
Syndax rises on FDA approval for blood cancer drug
Brief: Syndax Announces FDA Approval Of Revuforj® (Revumenib), The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A Kmt2a Translocation
U.S. STOCKS ON THE MOVE-Canadian National Railway, C.H. Robinson, Meta
Syndax Pharma falls as cancer therapy data fails to meet 'higher bar of expectations'
Syndax Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Syndax Pharmaceuticals Q3 EPS USD -84126
Syndax Pharmaceuticals Inc expected to post a loss of $1.11 a share - Earnings Preview
Syndax rises as FDA approves company's treatment for chronic graft-versus-host disease
Brief: Incyte, Syndax Get FDA Approval For Niktimvo (axatilimab-csfr)
Brief: Syndax Announces Publication In The Journal Of Clinical Oncology Of Data From The Pivotal Augment-101 Trial Of Revumenib
Syndax Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Syndax Pharmaceuticals Q2 EPS USD -0.8
Syndax Pharmaceuticals Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Syndax Announces PDUFA Action Date Extension For Revumenib NDA For Relapsed Or Refractory KMT2Ar Acute Leukemia
Brief: Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
Brief: Pyxis Oncology Expands Board Of Directors With Appointment Of Michael A. Metzger
Brief: Syndax Plans To Advance Into Phase 1B Portion Of Trial Evaluating Revumenib In Relapsed Or Refractory Metastatic MSS CRC
Syndax Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Syndax Pharmaceuticals Q1 EPS USD -0.85